MBRX News and Press, Moleculin Biotech Inc. From 12/21/23

2023-12-21 01:31:33 ET More on Moleculin Biotech Moleculin Biotech gains after early data for lead cancer therapy Seeking Alpha’s Quant Rating on Moleculin Biotech Historical earnings data for Moleculin Biotech Financial information for Moleculin Biote...

Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market PR Newswire HOUSTON , Dec. 20, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. (NASDAQ: MBRX) (Moleculin or the Company), a clinical stage ph...

Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting PR Newswire - CR rate of 36% in Intent to Treat or ITT (n=11) subjects with durability - CR rate of 44% in subjects treated with ...

2023-11-13 15:28:21 ET More on Moleculin Biotech Moleculin Biotech, Inc. (MBRX) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Moleculin Biotech Historical earnings data for Moleculin Biotech Financial information for Moleculin Biotec...

2023-11-13 12:59:02 ET Moleculin Biotech, Inc. (MBRX) Q3 2023 Earnings Conference Call November 13, 2023, 08:30 AM ET Company Participants Jenene Thomas - IR Walter Klemp - Chairman & CEO Paul Waymack - Senior CMO Jonathan Foster - EVP & CFO Con...

2023-11-13 10:59:58 ET More on Moleculin Biotech Seeking Alpha’s Quant Rating on Moleculin Biotech Historical earnings data for Moleculin Biotech Financial information for Moleculin Biotech For further details see: Moleculin Biotech Q3 GAAP EPS of ...

Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months PR Newswire – MB-106: CR rate of 38% (N=8) with durability u...

Moleculin Reports Third Quarter 2023 Financial Results PR Newswire – Ends Quarter with $24.6 million in Cash with Runway Estimated into Third Quarter of 2024 – Third quarter marked by additional positive clinical data from Annamycin lead development p...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

2023-11-10 14:16:55 ET More on Moleculin Biotech Seeking Alpha’s Quant Rating on Moleculin Biotech Historical earnings data for Moleculin Biotech Financial information for Moleculin Biotech For further details see: Moleculin Biotech Q3 2023 Earning...